Cardiol Therapeutics Inc Class A is seeing a rise in its stock price, which indicates growing interest from investors.
In the latest trading session, Cardiol Therapeutics Inc Class A (CRDL.TO) saw its stock increase by 0.67%, closing at CA$1.50. This positive movement comes as the investment community becomes more engaged with the company.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$165.99M
52W high
$2.33
52W low
$1.23
1W change
-1.96%
Beta
0.51
Analyst Price Targets
Based on analyst covering CRDL
Wall Street analysts forecast CRDL stock price to rise 300.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.00
+300.0% Upside
Current Price
C$1.50
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
35.1%
Annualized
90-Day Vol
58.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$1.25
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.41 | C$1.25 โ C$1.60 |
| 60 trading days | C$1.33 | C$1.12 โ C$1.58 |
| 90 trading days | C$1.25 | C$1.02 โ C$1.55 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Keep an eye on Cardiol Therapeutics as it takes part in important industry events and expands its clinical trial networks. These efforts could boost its visibility and credibility in the market.
Cardiol Therapeutics Inc Class A Gains 0.67% in Latest Trading Session
With a market cap of CA$171.76 million, Cardiol's stock remains a speculative investment, reflecting the risks that come with biotech companies.
Bull case
Cardiol's recent stock gains are largely due to its active participation in industry conferences and the acceptance of its Phase II MAvERIC trial results for publication. This signals strong potential for future growth.
Bear case
Despite the recent uptick, Cardiol Therapeutics operates in a highly competitive biotech field. Any delays or setbacks in clinical trials could hurt investor sentiment and stock performance.
Recent Developments
Cardiol Therapeutics has been actively involved in significant industry events, including the upcoming H.C. Wainwright 4th Annual BioConnect Investor Conference. These engagements are vital for building investor relations and showcasing the company's advancements.
Clinical Trial Progress
The acceptance of the Phase II MAvERIC trial results for publication in the Journal of the American Heart Association is a major milestone for Cardiol. This achievement not only validates their research efforts but also enhances their appeal to potential investors.
Market Context
As a small-cap biotech firm, Cardiol Therapeutics faces unique challenges and opportunities. The recent stock performance reflects investor optimism, but the volatile nature of the biotech sector means that potential investors should stay cautious and informed about ongoing developments.
Advertisement
